Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

IntroductionEndometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%–15% of women with EC are diagnosed with advanced-stage disease, resulting in a reported 5-year survival rate of only 17% for those with...

Full description

Bibliographic Details
Main Authors: Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
endometrial cancer
molecular classification
immune checkpoint inhibitors
dostarlimab
pembrolizumab plus lenvatinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1247291/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1247291/full

Similar Items